GRCE Straddle Strategy
GRCE (Grace Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE (Grace Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $35.2M, a beta of 0.37 versus the broader market, a 52-week range of 1.79-5.18, average daily share volume of 303K, a public-listing history dating back to 2012, approximately 5 full-time employees. These structural characteristics shape how GRCE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.37 indicates GRCE has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a straddle on GRCE?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
GRCE snapshot
As of August 14, 2026, spot at $2.17, ATM IV 232.90%, IV rank 45.13%, expected move 66.77%. The straddle on GRCE below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this straddle structure on GRCE specifically: GRCE IV at 232.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 66.77% (roughly $1.45 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GRCE expiries trade a higher absolute premium for lower per-day decay. Position sizing on GRCE should anchor to the underlying notional of $2.17 per share and to the trader's directional view on GRCE stock.
GRCE straddle setup
The GRCE straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GRCE at $2.17 on that close, the first option leg uses a $2.17 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GRCE chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GRCE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.17 | N/A |
| Buy 1 | Put | $2.17 | N/A |
GRCE straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
GRCE straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on GRCE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on GRCE
Straddles on GRCE are pure-volatility plays that profit from large moves in either direction; traders typically buy GRCE straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
GRCE thesis for this straddle
The market-implied 1-standard-deviation range for GRCE extends from approximately $0.72 on the downside to $3.62 on the upside. A GRCE long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current GRCE IV rank near 45.13% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on GRCE should anchor more to the directional view and the expected-move geometry. As a Healthcare name, GRCE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GRCE-specific events.
GRCE straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GRCE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GRCE alongside the broader basket even when GRCE-specific fundamentals are unchanged. Always rebuild the position from current GRCE chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on GRCE?
- A straddle on GRCE is the straddle strategy applied to GRCE (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With GRCE stock at $2.17 on the most recent close, the strikes shown on this page are snapped to the nearest listed GRCE chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are GRCE straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the GRCE straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 232.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GRCE straddle?
- The breakeven for the GRCE straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The GRCE market-implied 1-standard-deviation expected move in the same options snapshot is approximately 66.77%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on GRCE?
- Straddles on GRCE are pure-volatility plays that profit from large moves in either direction; traders typically buy GRCE straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current GRCE implied volatility affect this straddle?
- GRCE ATM IV is at 232.90% with IV rank near 45.13%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.